|
WO2020257017A1
|
|
Ingestible device with component capable of residing in the gastrointestinal tract
|
|
WO2020206170A1
|
|
Methods, systems, and compositions for counting nucleic acid molecules
|
|
WO2020106704A2
|
|
Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
|
|
WO2019246455A1
|
|
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
WO2019246273A1
|
|
Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
|
|
WO2019246317A1
|
|
Treatment of a disease or condition in a tissue originating from the endoderm
|
|
WO2019246271A1
|
|
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
WO2019246312A1
|
|
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
EP3810095A1
|
|
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
WO2019236915A1
|
|
Ingestible device with on-board fluorometer and related systems and methods
|
|
WO2019232295A1
|
|
Devices and systems for gastrointestinal microbiome detection and manipulation
|
|
AU2019247652A1
|
|
Methods, systems, and compositions for counting nucleic acid molecules
|
|
WO2019178071A1
|
|
Ingestible device with relatively large payload volume
|
|
WO2019147824A1
|
|
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
EP3723801A1
|
|
Treatment of a disease of the gastrointestinal tract with a s1p modulator
|
|
US2019079097A1
|
|
Preeclampsia biomarkers and related systems and methods
|
|
CN111094988A
|
|
Pre-eclampsia biomarkers and related systems and methods
|
|
WO2019036363A1
|
|
Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof
|
|
CN111225686A
|
|
Treatment of inflammatory diseases using ingestible devices to release immunomodulators
|
|
US2018296814A1
|
|
Administration of drugs to a patient
|
